Prospective study of changes in the metabolomic profiles of menduring their first three months of androgen deprivation therapy for prostate cancer

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3677-3685

  Saylor, Philip J ^a   Karoly, Edward D ^b   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b METABOLON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; ACETYLCARNITINE; ANDROGEN; BICALUTAMIDE; BILE ACID; CHOLESTEROL; GONADORELIN AGONIST; INSULIN; KETONE BODY; LEUPRORELIN; LIPID;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FATTY ACID OMEGA OXIDATION; GAS CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID OXIDATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TANDEM MASS SPECTROMETRY;

3-METHYL-2-OXOBUTANOATE DEHYDROGENASE (LIPOAMIDE); ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BILE ACIDS AND SALTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROXYBUTYRATES; INSULIN RESISTANCE; LEUPROLIDE; LIPID METABOLISM; MALE; METABOLOME; OXIDATION-REDUCTION; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; STEROIDS;

EID: 84863310009     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3209     Document Type: Article

References (37)

1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
2. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
3. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patientswith clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7. (Pubitemid 39079668)
4. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-50. (Pubitemid 41614795)
5. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90. (Pubitemid 40470408)
6. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504.
7. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-18.
8. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9. (Pubitemid 43779173)
9. Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 1997;158:1623-4.
10. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603. (Pubitemid 34158224)
11. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63:742-5. (Pubitemid 38479421)
12. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008;112:2188-94. (Pubitemid 351628628)
13. Kim H, Moreira D, Smith M, Presti JJ, Aronson W, Terris M, et al. A natural history of weight change in men with prostate cancer on androgen deprivation therapy: results from the SEARCH database. BJU Int 2010;107:924-8.
14. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-8.
15. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195-201. (Pubitemid 36238052)
16. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995;154:100-4.
17. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92-9.
18. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
19. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56. (Pubitemid 46630983)
20. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500. (Pubitemid 47463063)
21. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24. (Pubitemid 351767235)
22. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 2010.28:3448-56.
23. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009.27:3452-58.
24. Gall WE, Beebe K, Lawton KA, Adam KP, MitchellMW,Nakhle PJ, et al. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PloS One 2010;5: e10883.
25. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-26.
26. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
27. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/ electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009;81:6656-67.
28. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-7. (Pubitemid 32848544)
29. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011;108: 3270-5.
30. Landaas S. The formation of 2-hydroxybutyric acid in experimental animals. Clin Chim Acta 1975;58:23-32.
31. Walser M. Role of branched-chain ketoacids in protein metabolism. Kidney Int 1990;38:595-604. (Pubitemid 20299410)
32. Prawitt J, Caron S, Staels B. Bile Acid metabolism and the pathogenesis of type 2 diabetes. Cur Diab Rep 2011;11:160-6.
33. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56:239-47.
34. Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord 2010;8:179-88.
35. Prawitt J, Staels B. Bile acid sequestrants: glucose-lowering mechanisms. Metab Syndr Relat Disord 2010;8 Suppl 1:S3-8.
36. Rubinow KB, Snyder CN, Amory JK, Hoofnagle AN, Page ST. Acute testosterone deprivation reduces insulin sensitivity in men. Clin Endocrinol (Oxf) 2012;76:281-8.
37. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007;92:4254-9. (Pubitemid 350074740)